- Home
- BGLC vs CISS Comparison
BGLC vs CISS Comparison
Compare BGLC & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- CISS
- Stock Information
- Founded
- BGLC 2017
- CISS 2022
- Country
- BGLC Malaysia
- CISS Greece
- Employees
- BGLC N/A
- CISS N/A
- Industry
- BGLC Medical Specialities
- CISS Marine Transportation
- Sector
- BGLC Health Care
- CISS Consumer Discretionary
- Exchange
- BGLC Nasdaq
- CISS Nasdaq
- Market Cap
- BGLC 10.7M
- CISS 2.8M
- IPO Year
- BGLC N/A
- CISS N/A
- Fundamental
- Price
- BGLC $5.09
- CISS $3.35
- Analyst Decision
- BGLC
- CISS
- Analyst Count
- BGLC 0
- CISS 0
- Target Price
- BGLC N/A
- CISS N/A
- AVG Volume (30 Days)
- BGLC 2.7M
- CISS 125.1K
- Earning Date
- BGLC 08-13-2025
- CISS 08-21-2025
- Dividend Yield
- BGLC N/A
- CISS N/A
- EPS Growth
- BGLC N/A
- CISS N/A
- EPS
- BGLC N/A
- CISS N/A
- Revenue
- BGLC $9,265,870.00
- CISS $38,174,754.00
- Revenue This Year
- BGLC N/A
- CISS N/A
- Revenue Next Year
- BGLC N/A
- CISS N/A
- P/E Ratio
- BGLC N/A
- CISS N/A
- Revenue Growth
- BGLC N/A
- CISS N/A
- 52 Week Low
- BGLC $2.01
- CISS $2.85
- 52 Week High
- BGLC $15.60
- CISS $23.25
- Technical
- Relative Strength Index (RSI)
- BGLC 52.61
- CISS 44.02
- Support Level
- BGLC $5.33
- CISS $3.26
- Resistance Level
- BGLC $6.39
- CISS $3.49
- Average True Range (ATR)
- BGLC 1.18
- CISS 0.23
- MACD
- BGLC 0.10
- CISS -0.00
- Stochastic Oscillator
- BGLC 19.15
- CISS 28.72
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.